JP2022550459A5 - - Google Patents
Info
- Publication number
- JP2022550459A5 JP2022550459A5 JP2022520473A JP2022520473A JP2022550459A5 JP 2022550459 A5 JP2022550459 A5 JP 2022550459A5 JP 2022520473 A JP2022520473 A JP 2022520473A JP 2022520473 A JP2022520473 A JP 2022520473A JP 2022550459 A5 JP2022550459 A5 JP 2022550459A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- methyl
- octahydrocyclopenta
- pyran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962910863P | 2019-10-04 | 2019-10-04 | |
| US62/910,863 | 2019-10-04 | ||
| PCT/US2020/053942 WO2021067696A1 (en) | 2019-10-04 | 2020-10-02 | Antagonists of the muscarinic acetylcholine receptor m4 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022550459A JP2022550459A (ja) | 2022-12-01 |
| JP2022550459A5 true JP2022550459A5 (enExample) | 2023-10-11 |
| JP7572734B2 JP7572734B2 (ja) | 2024-10-24 |
Family
ID=75337550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022520473A Active JP7572734B2 (ja) | 2019-10-04 | 2020-10-02 | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12319701B2 (enExample) |
| EP (1) | EP4037677B1 (enExample) |
| JP (1) | JP7572734B2 (enExample) |
| AU (1) | AU2020358000B2 (enExample) |
| CA (1) | CA3155864A1 (enExample) |
| ES (1) | ES3057371T3 (enExample) |
| WO (1) | WO2021067696A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3651762B1 (en) | 2017-07-12 | 2024-07-03 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| JP7270989B2 (ja) | 2017-10-20 | 2023-05-11 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| CA3180717A1 (en) * | 2020-04-24 | 2021-10-28 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
| US20240174655A1 (en) * | 2021-04-02 | 2024-05-30 | Vanderbilt University | Indazole derivatives as antagonists of the muscarinic acetylcholine receptor m4 |
| WO2022261427A1 (en) * | 2021-06-11 | 2022-12-15 | Vanderbilt University | (4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-lambda6- sulfanone derivatives and similar compounds as muscarinic acetylcholine receptor m4 antagonists for the treatment of neurodegenerative disorders |
| CA3226995A1 (en) | 2021-07-21 | 2023-01-26 | Nico Therapeutics, Inc. | Annulated pyridazine compound |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7560551B2 (en) | 2006-01-23 | 2009-07-14 | Amgen Inc. | Aurora kinase modulators and method of use |
| EA018128B1 (ru) | 2006-01-23 | 2013-05-30 | Амген Инк. | Модуляторы аурора киназы, способы их получения и их применение |
| EP2038289A2 (en) * | 2006-04-21 | 2009-03-25 | Amgen Inc. | Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use |
| WO2011149995A1 (en) * | 2010-05-25 | 2011-12-01 | Abbott Laboratories | Novel substituted octahydrocyclopenta [c]pyrrol-4-amines as calcium channel blockers |
| WO2015027204A1 (en) * | 2013-08-23 | 2015-02-26 | Vanderbilt University | Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| BR112018016689A2 (pt) * | 2016-02-16 | 2019-02-12 | Univ Vanderbilt | moduladores alostéricos positivos do receptor muscarínico de acetilcolina m1 |
| PL3507289T3 (pl) | 2016-09-02 | 2021-01-25 | Suven Life Sciences Limited | Dodatnie allosteryczne modulatory receptora muskarynowego m1 |
| EP3651762B1 (en) | 2017-07-12 | 2024-07-03 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| JP7270989B2 (ja) | 2017-10-20 | 2023-05-11 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| ES2982890T3 (es) * | 2017-10-31 | 2024-10-18 | Univ Vanderbilt | Antagonistas del receptor muscarínico de acetilcolina M4 |
| CA3090130A1 (en) * | 2018-02-02 | 2019-08-08 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| WO2021119254A1 (en) | 2019-12-10 | 2021-06-17 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| AU2020402978A1 (en) | 2019-12-10 | 2022-06-23 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| US20230183219A1 (en) | 2020-04-24 | 2023-06-15 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
| CA3180717A1 (en) | 2020-04-24 | 2021-10-28 | Vanderbilt University | Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4 |
| CA3199786A1 (en) | 2020-11-18 | 2022-05-27 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| CN116669737A (zh) | 2020-12-22 | 2023-08-29 | 范德堡大学 | 毒蕈碱型乙酰胆碱受体m4的拮抗剂 |
| JP2024500880A (ja) | 2020-12-22 | 2024-01-10 | ヴァンダービルト ユニヴァーシティ | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| US20240174655A1 (en) | 2021-04-02 | 2024-05-30 | Vanderbilt University | Indazole derivatives as antagonists of the muscarinic acetylcholine receptor m4 |
| US20240228468A1 (en) | 2021-04-05 | 2024-07-11 | Vanderbilt University | N-(6-((octahydrocyclopenta[c]pyrrol-5-yi)amino)pyridazin-3-yl)phenyl)carboxamide and (6- ((octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)benzamide derivatives as machr m4 antagonists for the treatment of neurodegenerative disorders |
| WO2022261427A1 (en) | 2021-06-11 | 2022-12-15 | Vanderbilt University | (4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-lambda6- sulfanone derivatives and similar compounds as muscarinic acetylcholine receptor m4 antagonists for the treatment of neurodegenerative disorders |
-
2020
- 2020-10-02 US US17/766,341 patent/US12319701B2/en active Active
- 2020-10-02 ES ES20873262T patent/ES3057371T3/es active Active
- 2020-10-02 JP JP2022520473A patent/JP7572734B2/ja active Active
- 2020-10-02 AU AU2020358000A patent/AU2020358000B2/en active Active
- 2020-10-02 EP EP20873262.8A patent/EP4037677B1/en active Active
- 2020-10-02 WO PCT/US2020/053942 patent/WO2021067696A1/en not_active Ceased
- 2020-10-02 CA CA3155864A patent/CA3155864A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019283921B2 (en) | Indole carboxamide compounds useful as kinase inhibitors | |
| AU2002346300B2 (en) | Diamine derivatives | |
| KR102093608B1 (ko) | 이미다조피리딘 화합물 | |
| JP5352458B2 (ja) | ヒスタミンｈ４受容体のベンゾフロ−およびベンゾチエノピリミジン系モジュレーター | |
| ES2380395T3 (es) | Triazolopiridinas como inhibidores de fosfodiesterasa para el tratamiento de enfermedades dérmicas | |
| US9102686B2 (en) | 5,6,7,8,9,10-hexahydro-6,10-epimino[1,2,4]triazolo[4,3-a]azocines as P2X7 modulators | |
| JP6936224B2 (ja) | オクタヒドロピロロ［３，４−ｃ］ピロール誘導体およびその使用 | |
| JP2015514073A5 (enExample) | ||
| US10047092B2 (en) | Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators | |
| AU2015335783B2 (en) | Tricyclic atropisomer compounds | |
| JP2021534108A5 (enExample) | ||
| JP2014528433A5 (enExample) | ||
| HRP20180592T1 (hr) | Novi biciklički derivati dihidrokinolin-2-ona | |
| JP2024542610A5 (enExample) | ||
| JP2006515844A5 (enExample) | ||
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| JP2012512192A (ja) | 皮膚疾患の処置のためのホスホジエステラーゼ阻害薬としてのトリアゾロピリジン誘導体 | |
| JP2024543973A5 (enExample) | ||
| JP2021513519A5 (enExample) | ||
| JP2022549601A5 (enExample) | ||
| JP2005515976A5 (enExample) | ||
| JP2023552838A5 (enExample) | ||
| JP2008508365A5 (enExample) | ||
| JP2026515444A (ja) | Ｋｃｃ２増強剤及びその使用 | |
| AU2017321416B2 (en) | Hydroxynorketamine derivatives for the treatment of disorders |